Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    7
    ...
ATC Name B/G Ingredients Dosage Form Price
M01AX21 ART G Diacerein - 50mg 50mg Capsule 1,146,298 L.L
D06AX01 ACIDE FUSIDIQUE BGR G Fusidic acid - 2% 2% Cream 202,920 L.L
N02BE01 ADOL G Paracetamol - 120mg/5ml 120mg/5ml Syrup 126,321 L.L
L01BC07 AZACITIDINE ARROW G Azacitidine - 25mg/ml 25mg/ml Injectable suspension 10,967,854 L.L
M02AA10 ACHONID GEL G Ketoprofen - 2.5% 2.5% Gel 179,179 L.L
C01CA24 ADRENALINE 1 MG I.V. G Adrenaline - 1mg/ml 1mg/ml Injectable solution 2,239,738 L.L
C08DB01 APO-DILTIAZ G Diltiazem HCl - 60mg 60mg Tablet 545,600 L.L
L01BC07 AZACITIDINE EVER PHARMA G Azacitidine - 100mg/100ml 25mg/ml Injectable powder for suspension 10,967,854 L.L
C01CA24 ADRENALINE RENAUDIN G Epinephrine (tartrate) - 1mg/ml 1mg Injectable solution 444,812 L.L
L01BC07 AZACITIDINE NEAPOLIS G Azacitidine - 100mg 100mg Injectable lyophilised powder 9,401,575 L.L
C01CA24 ADRENALINE SALF G Adrenaline - 1mg/ml 1mg/ml Injectable solution 220,390 L.L
L01BC07 AZACITIDINE SHILPA G Azacitidine - 100mg 100mg Injectable powder 7,350,062 L.L
C01CA24 ADRENALINE AGUETTANT G Adrenaline - 0.1mg/ml 0.1mg/ml Injectable solution 13,990,891 L.L
L01BC07 AZACITIDINE SPC G Azacitidine - 100mg 100mg Injectable powder 10,706,993 L.L
R03AK13 AEROCORT-A HFA G Salbutamol - 100mcg/dose, Beclometasone - 50mcg/dose Metered dose inhaler 541,569 L.L
C09AA01 APO-CAPTO G Captopril - 25mg 25mg Tablet, scored 1,132,859 L.L
D06AX09 AVALON AVOBAN G Mupirocin - 2% w/w 2% Ointment 460,938 L.L
J01DH02 ARCHIFAR G Meropenem - 500mg 500mg Injectable powder for solution 6,443,725 L.L
J01DH02 AROPEM G Meropenem (trihydrate) - 0.5g 0.5g Injectable powder for solution 995,723 L.L
J01DH02 AROPEM G Meropenem - 0.5g 0.5g Injectable powder for solution 995,723 L.L
N02BE01 ADOL G Paracetamol - 250mg/5ml 250mg/5ml Suspension, alcohol free 192,169 L.L
S01AA26 AZYTER G Azithromycin (dihydrate) - 15mg/g 15mg/g Drops solution 412,560 L.L
J01DH02 AROPEM G Meropenem - 0.5g 0.5g Injectable powder for solution 995,723 L.L
J01DH02 AROPEM G Meropenem - 0.5g 0.5g Injectable powder for solution 19,022,727 L.L
C09AA01 APO-CAPTO G Captopril - 50mg 50mg Tablet, scored 1,752,371 L.L
J01DH02 ARCHIFAR G Meropenem - 1g 1g Injectable powder for solution 6,443,725 L.L
J01DH02 AROPEM G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 995,723 L.L
A02BC01 ARAPRIDE G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 427,342 L.L
J01DH02 AROPEM G Meropenem - 1g 1g Injectable powder for solution 995,723 L.L
A02BC01 AXIPRON G Omeprazole - 20mg 20mg Capsule 373,358 L.L
    ...
    7
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026